| Pharmaceuticals | Branded and generic formulations in respiratory, antiretroviral, cardiology, oncology, CNS, and anti-infective therapies. | Strong R&D, global regulatory approvals, diversified geographic presence, and robust manufacturing footprint. | B2B and B2C; hospitals, clinics, pharmacies, governments, and patients in regulated and emerging markets. | Specialty and biosimilar drugs, respiratory and oncology therapies. | 26244 | 95 | Revenue primarily via product sales to hospitals, pharmacies, and governments globally. | Primarily direct sales and supply contracts; competitive pricing with some tiered/government tenders. | Strong demand for respiratory and specialty drugs, new launches, and expanding market access. | Foracort, Indaflo, Cipladine, Hepcvir-L, Albuterol inhaler |
| New ventures | Consumer healthcare products, digital diagnostics, wellness therapeutics, and emerging biotech initiatives. | Innovation in digital health and diagnostics, expanding consumer base, and integration with pharmaceutical offerings. | B2C primarily with increasing focus on digital health consumers and wellness markets. | Digital diagnostics and specialty consumer health products. | 1303 | 5 | Product sales, digital service offerings, licensing and strategic partnerships. | Combination of direct sales, subscription-based digital services, and licensing. | Consumer health demand, digital health expansion, wellness products, and technology-enabled solutions. | Cipla Digital Health, Consumer Health brands |
